ArticleClinicoEconomics and outcomes research : CEOR2011

Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy.

Gerald Hj Mickisch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.